Complete Story
Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for pediatric patients
On August 24, 2022, the Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.
For more information, read the FDA Announcement or Press Release.